Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD

Video

Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.

Related Videos
Related Content
I-SCREEN project set to use AI for AMD diagnosis across Europe

I-SCREEN project set to use AI for AMD diagnosis across Europe

April 17th 2024
Article
India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD

India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD

April 14th 2024
Article
EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901

EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901

April 11th 2024
Article
John Han, PharmD named Vice President, Medical Affairs for Opthea Limited

John Han, PharmD named Vice President, Medical Affairs for Opthea Limited

April 10th 2024
Article
Clinical trials: Companies tackle AMD in early 2024

Clinical trials: Companies tackle AMD in early 2024

April 2nd 2024
Article
Understanding the risks: 4 factors that may contribute to AMD

Understanding the risks: 4 factors that may contribute to AMD

March 30th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.